Tujunga, CA, United States of America

Sangkil Nam

This inventor holds 18 USPTO granted patents and 5 published patent applications and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Beckman Research Institute, City of Hope, University of California, National and Kapodistrian University of Athens. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sangkil Nam. Retrieved from https://idiyas.com/inventor/sangkil-nam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 88.9

 

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 32(Granted Patents)


Location History:

  • South Pasadena, CA (US) (2014 - 2016)
  • Monrovia, CA (US) (2009 - 2017)
  • Tijunga, CA (US) (2018)
  • Duarte, CA (US) (2016 - 2022)
  • Tujunaga, CA (US) (2023)
  • Tujunga, CA (US) (2016 - 2024)

Company Filing History:


Years Active: 2009-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Indirubin Derivatives
T-cell Lymphoma Treatments
Dithio ETP Derivatives
Pyridopyrazine Compounds
Isatin Derivatives
Berbamine Derivatives
Pharmaceutical Compositions
Chronic Myelogenous Leukemia
Synthesis
Analog Compounds
18 patents (USPTO):Explore Patents

Title: Celebrating the Innovations of Inventor Sangkil Nam

Introduction: Sangkil Nam is a notable inventor based in Tujunga, California, recognized for his significant contributions to the field of cancer treatment. With a total of 18 patents to his name, Nam's work focuses on developing innovative therapies that address critical healthcare challenges.

Latest Patents: Among Sangkil Nam's latest patents are groundbreaking compositions aimed at treating various forms of cancer. One such patent, titled "5-Bromo-indirubins," outlines compositions and methods specifically designed to target FLT3-AML and chronic myeloid leukemia (CML). Additionally, he has developed treatment methods for T-cell lymphoma, comprising the administration of an ETP compound to subjects in need. These advancements highlight Nam's commitment to improving treatment options for patients suffering from serious illnesses.

Career Highlights: Throughout his career, Sangkil Nam has been associated with esteemed organizations that facilitate cutting-edge research and innovation. Notably, he has worked at the City of Hope, a pioneering cancer research and treatment center, as well as the University of California, where he contributed to various scientific endeavors.

Collaborations: Nam's impactful work has led him to collaborate with renowned professionals in his field, including David A. Horne and Richard Jove. These collaborations have not only enriched his research but also broadened the horizons of medical and scientific knowledge.

Conclusion: Sangkil Nam's dedication to innovation and his impressive track record of patent contributions underline his vital role in advancing cancer treatment methodologies. As he continues to develop and refine his ideas, his innovations promise to impact many lives positively, showcasing the power of invention in improving healthcare outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…